A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Geron Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 781,723 shares of GERN stock, worth $3.32 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
781,723
Holding current value
$3.32 Million
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$3.1 - $5.09 $2.42 Million - $3.98 Million
781,723 New
781,723 $3.31 Million
Q4 2022

Feb 13, 2023

BUY
$2.03 - $2.42 $48,922 - $58,322
24,100 Added 10.31%
257,800 $624,000
Q3 2022

Nov 14, 2022

BUY
$1.67 - $2.94 $37,575 - $66,150
22,500 Added 10.65%
233,700 $547,000
Q2 2022

Aug 12, 2022

SELL
$1.19 - $1.65 $513,009 - $711,315
-431,100 Reduced 67.12%
211,200 $327,000
Q1 2022

May 13, 2022

BUY
$0.99 - $1.6 $391,644 - $632,960
395,600 Added 160.36%
642,300 $874,000
Q4 2021

Feb 11, 2022

BUY
$1.22 - $1.72 $300,974 - $424,324
246,700 New
246,700 $301,000
Q1 2021

May 13, 2021

SELL
$1.52 - $2.1 $1.49 Million - $2.06 Million
-982,500 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$1.55 - $2.05 $1.49 Million - $1.97 Million
961,624 Added 4606.36%
982,500 $1.56 Million
Q3 2020

Nov 13, 2020

SELL
$1.59 - $2.19 $11,607 - $15,987
-7,300 Reduced 25.91%
20,876 $36,000
Q2 2020

Aug 13, 2020

BUY
$1.05 - $2.18 $29,584 - $61,423
28,176 New
28,176 $61,000
Q1 2020

May 14, 2020

SELL
$0.89 - $1.49 $51,014 - $85,406
-57,320 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$1.27 - $1.54 $72,796 - $88,272
57,320 New
57,320 $78,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.61B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.